English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The present study was performed to investigate if the generic of valproic acid delayed release is interchangeable on the basis bioequivalence to the reference product. Due to previous report of breakthrough seizures following a change from a brand name product to a generic product, this bioequivalence study was conducted using tightened acceptance criteria for assuring the therapeutic equivalence. Twenty eight healthy volunteers participated in an open-label, randomized and two-way crossover study under fasting conditions. Plasma samples were collected up 72 hours following drug administration and were determined by liquid chromatography-tandem mass spectrometry. Pharmacokinetic parameters used for bioequivalence assessment were AUC0-t, AUC0∞, and Cmax. The 90% CI bioequivalence limits was tightened from the traditional 80.00% -125.00% to 90.00%-111.11%. All volunteers completed the study. The 90% confidence intervals obtained by analysis of variance for AUC0-t, AUC0-∞, and Cmax were 98.38%-104.61%, 98.93%-105.31%, and 92.62%-102.93%, respectively. Both formulations were tolerated and no serious adverse events were reported. These results were all within the range of 90.00-111.11%. The low intra-subject variability observed in this study indicates that tightened acceptance criteria are still applicable for valproic acid BE study.

Comparative bioavailaibilty of two valproic acid delayed-release tablets in healthy volunteers with tighter acceptance criteria to anticipate breakthrough seizures